AxoGen (NASDAQ:AXGN) and Second Sight Medical Products (NASDAQ:EYES) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.
This table compares AxoGen and Second Sight Medical Products’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Second Sight Medical Products||-418.82%||-432.45%||-232.22%|
This is a breakdown of recent ratings and target prices for AxoGen and Second Sight Medical Products, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Second Sight Medical Products||0||0||1||0||3.00|
AxoGen presently has a consensus target price of $44.67, indicating a potential upside of 33.29%. Second Sight Medical Products has a consensus target price of $5.00, indicating a potential upside of 218.47%. Given Second Sight Medical Products’ higher possible upside, analysts plainly believe Second Sight Medical Products is more favorable than AxoGen.
Risk & Volatility
AxoGen has a beta of -0.39, indicating that its stock price is 139% less volatile than the S&P 500. Comparatively, Second Sight Medical Products has a beta of 3.07, indicating that its stock price is 207% more volatile than the S&P 500.
Institutional & Insider Ownership
83.0% of AxoGen shares are owned by institutional investors. Comparatively, 10.8% of Second Sight Medical Products shares are owned by institutional investors. 7.9% of AxoGen shares are owned by insiders. Comparatively, 34.7% of Second Sight Medical Products shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares AxoGen and Second Sight Medical Products’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|AxoGen||$60.43 million||21.25||-$10.44 million||($0.31)||-108.10|
|Second Sight Medical Products||$7.96 million||13.23||-$28.51 million||($0.59)||-2.66|
AxoGen has higher revenue and earnings than Second Sight Medical Products. AxoGen is trading at a lower price-to-earnings ratio than Second Sight Medical Products, indicating that it is currently the more affordable of the two stocks.
AxoGen beats Second Sight Medical Products on 9 of the 13 factors compared between the two stocks.
AxoGen, Inc. develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
About Second Sight Medical Products
Second Sight Medical Products, Inc. develops, manufactures and markets prosthetic devices. Its product the Argus II System, treats outer retinal degenerations and employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The firm’s system works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina. The company was founded by Alfred E. Mann, Aaron Mendelsohn, Sam Williams, Robert J. Greenberg and Gunnar Bjorg in 1998 and is headquartered in Sylmar, CA.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.